NDAORALTABLET, CHEWABLE
Approved
Nov 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
VELPHORO (sucroferric oxyhydroxide) by Fresenius Kabi is phosphate chelating activity [moa]. First approved in 2013.
Drug data last refreshed 17m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VELPHORO (sucroferric oxyhydroxide) is an oral chewable phosphate binder approved in 2013 for managing hyperphosphatemia in patients with chronic kidney disease on dialysis. It works by chelating dietary phosphate in the gastrointestinal tract, preventing absorption and reducing serum phosphate levels.
$0.466BPart D
Peak8.9 years to LOEVELPHORO is in peak commercial phase with $466M in annual Part D spending, indicating a mature, stable franchise with established sales infrastructure and commercial team.
Mechanism of Action
Phosphate Chelating Activity
Pharmacologic Class:
Phosphate Binder
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients
Started Feb 2020
17 enrolled
Peritoneal Dialysis ComplicationHyperphosphatemiaHypoalbuminemia
Why This Matters for Your Career
Worked on VELPHORO at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.